Relationships between body condition score, body weight and body measurements in alpacas.

BACKGROUND: The nutritional status in alpacas is often masked by their dense fibre coat. Its assessment is commonly approached by different body condition scores (BCS) that rely on manual palpation of defined anatomical regions. However, BCS is an important diagnostic tool to aid recognition of diseased South American camelids (SACs) and low BCS has been associated with conditions like anaemia and neutrophilia. For dose-dependent veterinary treatment, body weight (BW), that should be as accurate as possible, is required. As on-site weighing with scales is often not possible, BW can mostly only be roughly estimated. To date, it remains unclear whether BCS in alpacas provides reliable information on BW or the ratios of BW to body length commonly known as Body Mass Index (BMI) or Ponderal Index (PI). Equations to estimate BW based on body measurements are available in the literature. Nonetheless, respective equations were developed in growing alpacas or adult llamas and BCS was not included. RESULTS: To compare six different BCS approaches and to examine the relationship between BCS and BW, body measurements and BCS scores were recorded in a herd of 105 alpacas. The examined BCS approaches showed significant (p < 0.05) but poor to moderate positive correlations to BW, BMI or PI. A solely visual inspection of BCS, in contrast, was not correlated with BW, BMI or PI. Equations previously developed in other studies provided an accurate estimation of BW. Multiple linear regression showed that the accuracy in predicting BW could be further increased by adding BCS data and sex. CONCLUSION: Our observations indicate that most selected BCS approaches are not only important measures of nutritional status but can also be used to create more accurate models for BW calculation in alpacas. The study also supports the claim that a purely visual inspection of alpacas is not an adequate method to evaluate the nutritional status of these animals.

Oral vaccination of dogs with recombinant rabies virus vaccines.

Oral rabies virus (RV) vaccines are used to immunize a diversity of mammalian carnivores, but no single biological is effective for all major species. Recently, advances in reverse genetics have allowed the design of recombinant RV for consideration as new vaccines. The objective of this experiment was to examine the safety, immunogenicity and efficacy of recombinant RV vaccines administered to captive dogs by the oral route, compared to a commercial vaccinia-rabies glycoprotein (V-RG) recombinant virus vaccine. Animals consisted of naive purpose-bred beagles of both sexes, and were 6 months of age or older. Dogs were randomly assigned to one of six groups, and received either diluent or vaccine (PBS; V-RG; RV SN10-333; RV SPBN-Cyto c; RV SPBNGA; RV SPBNGAGA), with at least six animals per group. On day 0, 1 ml of each vaccine (or PBS) was administered to the oral cavity of each dog, at an approximate concentration of 10(8) to 10(9) TCID50. After vaccination, dogs were observed daily and bled weekly, for 5 weeks, prior to RV challenge. No signs of illness related to vaccination were detected during the observation period. Excluding the controls, RV neutralizing antibodies were detected in the majority of animals within 1-2 weeks of primary vaccination. Thereafter, all dogs were inoculated in the masseter muscle with a street virus of canine origin. All control animals developed rabies, but no vaccinates succumbed, with the exception of a single dog in the V-RG group. Review of these preliminary data demonstrates the non-inferiority of recombinant RV products, as concerns both safety and efficacy, and supports the suggestion that these vaccines may hold promise for future development as oral immunogens for important carnivore species, such as dogs.

Estimating the global burden of endemic canine rabies.

BACKGROUND: Rabies is a notoriously underreported and neglected disease of low-income countries. This study aims to estimate the public health and economic burden of rabies circulating in domestic dog populations, globally and on a country-by-country basis, allowing an objective assessment of how much this preventable disease costs endemic countries. METHODOLOGY/PRINCIPAL FINDINGS: We established relationships between rabies mortality and rabies prevention and control measures, which we incorporated into a model framework. We used data derived from extensive literature searches and questionnaires on disease incidence, control interventions and preventative measures within this framework to estimate the disease burden. The burden of rabies impacts on public health sector budgets, local communities and livestock economies, with the highest risk of rabies in the poorest regions of the world. This study estimates that globally canine rabies causes approximately 59,000 (95% Confidence Intervals: 25-159,000) human deaths, over 3.7 million (95% CIs: 1.6-10.4 million) disability-adjusted life years (DALYs) and 8.6 billion USD (95% CIs: 2.9-21.5 billion) economic losses annually. The largest component of the economic burden is due to premature death (55%), followed by direct costs of post-exposure prophylaxis (PEP, 20%) and lost income whilst seeking PEP (15.5%), with only limited costs to the veterinary sector due to dog vaccination (1.5%), and additional costs to communities from livestock losses (6%). CONCLUSIONS/SIGNIFICANCE: This study demonstrates that investment in dog vaccination, the single most effective way of reducing the disease burden, has been inadequate and that the availability and affordability of PEP needs improving. Collaborative investments by medical and veterinary sectors could dramatically reduce the current large, and unnecessary, burden of rabies on affected communities. Improved surveillance is needed to reduce uncertainty in burden estimates and to monitor the impacts of control efforts.